Navigation Links
Leg Ulcers-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leg Ulcers-Pipeline Insights, 2014

http://www.reportlinker.com/p02278621/-Leg-Ulcers-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Leg Ulcers-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Leg Ulcers. This report provides information on the therapeutic development based on the Leg Ulcers dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Leg Ulcers
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Leg Ulcers pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Leg Ulcers and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Leg Ulcers
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Leg Ulcers pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Leg Ulcers Overview
- Leg Ulcers Pipeline Therapeutics
- Leg Ulcers Therapeutics under Development by Companies
- Leg Ulcers Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Leg Ulcers Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Leg Ulcers Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Leg Ulcers Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Leg Ulcers – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leg Ulcers – Discontinued Products
- Leg Ulcers – Dormant Products
- Companies Involved in Therapeutics Development for Leg Ulcers
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Leg Ulcers, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Leg Ulcers Assessment by Monotherapy Products
- Leg Ulcers Assessment by Combination Products
- Leg Ulcers Assessment by Route of Administration
- Leg Ulcers Assessment by Stage and Route of Administration
- Leg Ulcers Assessment by Molecule Type
- Leg Ulcers Assessment by Stage and Molecule Type
- Leg Ulcers Therapeutics – Discontinued Products
- Leg Ulcers Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Leg Ulcers, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Leg Ulcers Assessment by Monotherapy Products
- Leg Ulcers Assessment by Combination Products
- Leg Ulcers Assessment by Route of Administration
- Leg Ulcers Assessment by Stage and Route of Administration
- Leg Ulcers Assessment by Molecule Type
- Leg Ulcers Assessment by Stage and Molecule Type

To order this report: Leg Ulcers-Pipeline Insights, 2014
http://www.reportlinker.com/p02278621/-Leg-Ulcers-Pipeline-Insights-2014.html
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Adenocarcinoma-Pipeline Insights, 2014
2. Lung Disease-Pipeline Insights, 2014
3. Liver Transplantation-Pipeline Insights, 2014
4. Liver Fibrosis-Pipeline Insights, 2014
5. Liver Diseases-Pipeline Insights, 2014
6. Liver Cirrhosis-Pipeline Insights, 2014
7. Liposarcoma -Pipeline Insights, 2014
8. Lipodystrophy-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
(Date:4/27/2016)... 27, 2016 Tie-up with Government ... to save newborns   Fortis La ... newborns in collaboration with Breast Milk Foundation (BMF), a non-profit ... Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre ... for infants and should be available to babies deprived of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April 30, marks World ... on public health. The World Veterinary Association (WVA) and the World Organization for ... continuing education with a One Health focus, which emphasizes how veterinarians pursue continuing ...
(Date:4/30/2016)... ... ... for all of us, but there are things we can do to improve the odds of ... more and more that there are simple, yet important steps that can be taken to maintain ... Kohli’s recommends for her patients include;, , exercise , ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... Mercy College ... campus. The following programs will be expanding due to high demand: Master of ... The expansion will begin this summer. , School of Business Graduate Program ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation for ... first accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
Breaking Medicine News(10 mins):